JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (1998) 159, 15-25       DOI: 10.1677/joe.0.1590015
© 1998 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dominici, F.
Right arrow Articles by Turyn, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dominici, F.
Right arrow Articles by Turyn, D
Journal of Endocrinology, Vol 159, Issue 1, 15-25
Copyright © 1998 by Society for Endocrinology


Articles

Role of hyperinsulinemia on hepatic insulin receptor concentration and autophosphorylation in the presence of high growth hormone levels in transgenic mice overexpressing growth hormone gene

FP Dominici, A Balbis, A Bartke, and D Turyn


Overexpression of bovine growth hormone (bGH) in transgenic (PEPCK-bGH) mice induces resistance to insulin, which is compensated by a major increase in insulin levels. In these animals, hepatic insulin receptors (InsRs) are downregulated while tyrosine kinase activity of wheat germ agglutinin (WGA)-purified InsRs towards exogenous substrates is unexpectedly increased. By normalizing insulinemia, we attempted to determine whether the alterations detected in the early steps of insulin signal transduction are due to exposure to chronically high GH levels or are secondary to hyperinsulinemia. Transgenic PEPCK-bGH animals were treated with a single intraperitoneal administration of streptozotocin (STZ) or were deprived of food for 48 h, to normalize insulin levels. Both fasting and STZ treatment were effective in reducing insulin blood levels to control values or below, while GH levels remained unchanged (STZ treatment) or increased (fasted animals). In the liver of untreated transgenic mice, the number of InsRs as determined by 125I-insulin binding was significantly diminished (65+/-5% and 60+/-6% of normal values in microsomes and solubilized membranes respectively;P<0.01 vs control mice). In treated transgenic mice, the number of InsRs increased to values similar to or slightly higher than those found in normal control mice (STZ-treated: 139+/-26% and 126+/-8%; fasted: 128+/-5% (P<0.05) and 102+/-1.5%, for microsomes and solubilized membranes respectively). Neither treatment altered InsR affinity. InsR concentration in liver as determined by immunoblotting using an antibody against the beta-subunit of the insulin receptor was found to be reduced in transgenic mice (69+/-3% of normal values,P<0.001) and was normalized after both STZ treatment (105+/-4%) and fasting (109+/-4%). Insulin-stimulated autophosphorylation activity of InsRs in transgenic mice was increased (154+/-13%,P<0.01 compared with the control group), essentially normalized by STZ treatment (96+/-14%), and reduced by fasting, to below the values measured in normal control mice (56+/-15%,P<0.05). The potential influence of basal serine/threonine (Ser/Thr) phosphorylation of the InsR beta-subunit on the regulation of the InsRs from transgenic mice was also investigated. The autophosphorylation activity of WGA-purified InsRs from all groups of mice studied was essentially unchanged after dephosphorylation with alkaline phosphatase or mild trypsinization. Consequently, our results suggest that the observed changes in InsR number and autophosphorylation activity in the liver of bGH transgenic mice are directly related to changes in insulin blood levels, and that Ser/Thr phosphorylation is apparently not involved in the regulation of the InsR autophosphorylation activity in this model of insulin resistance.


This article has been cited by other articles:


Home page
EndocrinologyHome page
Y. Cho, M. Ariga, Y. Uchijima, K. Kimura, J.-Y. Rho, Y. Furuhata, F. Hakuno, K. Yamanouchi, M. Nishihara, and S.-I. Takahashi
The Novel Roles of Liver for Compensation of Insulin Resistance in Human Growth Hormone Transgenic Rats
Endocrinology, November 1, 2006; 147(11): 5374 - 5384.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
F. P. Dominici and D. Turyn
Growth Hormone-Induced Alterations in the Insulin-Signaling System
Experimental Biology and Medicine, March 1, 2002; 227(3): 149 - 157.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
A. Bartke, V. Chandrashekar, D. Turyn, R. W. Steger, L. Debeljuk, T. A. Winters, J. A. Mattison, N. A. Danilovich, W. Croson, D. R. Wernsing, et al.
Effects of Growth Hormone Overexpression and Growth Hormone Resistance on Neuroendocrine and Reproductive Functions in Transgenic and Knock-Out Mice
Experimental Biology and Medicine, November 1, 1999; 222(2): 113 - 123.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
F. P. Dominici, D. Cifone, A. Bartke, and D. Turyn
Alterations in the early steps of the insulin-signaling system in skeletal muscle of GH-transgenic mice
Am J Physiol Endocrinol Metab, September 1, 1999; 277(3): E447 - E454.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Society for Endocrinology.